RegeneRx (Bethesda, Maryland) said that its stock would begin trading on the American Stock Exchange (Amex) on March 28 under the symbol RGN. The company's shares will continue to be traded on the OTC Bulletin Board until that time.

"We're pleased to be listed on the American Stock Exchange, as it should increase the company's visibility on Wall Street and provide greater trading liquidity for institutional investors," said J.J. Finkelstein, president and CEO. "The fact that we have significantly increased stockholder equity and have a higher market capitalization, both of which are required for listing on the Amex, are milestones we're pleased to have attained."

RegeneRx is a biopharmaceutical company developing TB4 as a platform technology for the treatment of acute and chronic wounds and for a variety of human diseases involving tissue and organ repair under an exclusive worldwide license from the National Institutes of Health (Bethesda, Maryland).